BrightSpring Health Services, Inc.
BrightSpring provides pharmacy and provider services to people with complex health needs, particularly seniors and specialty populations, including people with behavioral health needs. Its services are delivered mainly in patients’ homes and community settings to Medicare, Medicaid and commercially insured populations. The company operates in all 50 states and is headquartered in Louisville, Kentucky. BrightSpring has two reportable segments: Pharmacy Solutions and Provider Services. Pharmacy Solutions includes infusion and specialty pharmacy, home and community pharmacy, and medication management. Provider Services includes home health, hospice, rehabilitation therapy, home-based primary care and supportive personal care. The company earns money by providing these services to patients and customers, including through pharmacy contracts and clinical and supportive care. It also offers coordinated care that combines pharmacy and provider services.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BTSG in the last 30 days.
See all $BTSG insider activity →Guggenheim raised its price target on BrightSpring Health Services (BTSG) to $84 from $81, maintaining a Buy rating. The company reported strong Q3 2026 results, with revenue growth of 26% and earnings of $0.54 per share, exceeding expectations. Management expects 15-20% organic EBITDA growth in 2027. Analysts remain optimistic, with a consensus Strong Buy rating and targets ranging from $70 to $92.
BTSG reported Q3 revenue of $4.21B, beating estimates by 8.9%, and raised full-year revenue guidance to $16.01B. Adjusted EPS and EBITDA also exceeded expectations. Growth was driven by specialty pharmacy, home health, and operational efficiencies. The company plans continued M&A and technology investments.
UBS increased its price target for BrightSpring Health Services (BTSG) to $92 from $85, citing growth prospects in its Specialty Pharmacy and Infusion businesses. The stock has surged 102% over the past year. The company reported Q3 2026 earnings of $0.54 per share, beating estimates, and raised its 2026 revenue guidance to $15.9B-$16.125B. Goldman Sachs also raised its target to $90, highlighting strong growth.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning BTSG (BrightSpring Health Services, Inc.). Coverage has skewed bullish: 5 bullish, 0 neutral, and 0 bearish.
Recent BTSG coverage spans earnings, regulation and financial news.
Guidance lift and strong earnings likely support upside.
Earnings beat and upward guidance suggest upside potential.
Analyst upgrades and strong earnings suggest upside potential.
Positive analyst upgrade and guidance raise suggest upside potential.
BTSG is discussed as a source for how CMS anti-fraud policy mechanics could affect home health operators, but no BTSG-specific policy decision is announced.
AlphAI scores every news story that mentions BTSG with an AI model for sentiment and relevance, and aggregates insider trades from BrightSpring Health Services, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Guggenheim raised its price target on BrightSpring Health Services (BTSG) to $84 from $81, maintaining a Buy rating. The company reported strong Q3 2026 results, with revenue growth of 26% and earnings of $0.54 per share, exceeding expectations. Management expects 15-20% organic EBITDA growth in 2027. Analysts remain optimistic, with a consensus Strong Buy rating and targets ranging from $70 to $92.
BTSG reported Q3 revenue of $4.21B, beating estimates by 8.9%, and raised full-year revenue guidance to $16.01B. Adjusted EPS and EBITDA also exceeded expectations. Growth was driven by specialty pharmacy, home health, and operational efficiencies. The company plans continued M&A and technology investments.
UBS increased its price target for BrightSpring Health Services (BTSG) to $92 from $85, citing growth prospects in its Specialty Pharmacy and Infusion businesses. The stock has surged 102% over the past year. The company reported Q3 2026 earnings of $0.54 per share, beating estimates, and raised its 2026 revenue guidance to $15.9B-$16.125B. Goldman Sachs also raised its target to $90, highlighting strong growth.
Goldman Sachs raised its price target for BrightSpring Health (BTSG) to $90, citing strong Q3 2026 results and raised 2026 revenue guidance to $15.9B-$16.125B. The company's EPS beat estimates by 170%, with revenue up 26% YoY. BTSG shares rose 13.6% in a week and 102% in a year.
CMS is considering options for its home health enrollment freeze, including a 'gold card' approach for compliant providers and geographic limits. The final rule, with a 2.4% payment increase and a 3% temporary reduction, is awaited. BrightSpring Health Services (BTSG) was mentioned in discussions about fraud and compliance.
BrightSpring reported Q3 2026 revenue of $4.21B, up 26.4% YoY, with net income of $101M. Adjusted EBITDA rose 42.0% to $228M. The company raised its full-year 2026 revenue and EBITDA guidance. Pharmacy Solutions and Provider Services saw significant growth, and the company completed the divestiture of its Community Living business.
BrightSpring Health Services, Inc. (BTSG) filed an SEC Form 8-K — Results of Operations and Financial Condition. BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results and Increases Full Year 2026 Guidance LOUISVILLE, Ky., October 30, 2026 — BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home- and community
Brightspring Health Services Inc. (BTSG) is set to report Q3 earnings, with analysts expecting $0.20 EPS, up 17.65% YoY. Revenue in Q2 was $3.87B, up 23% YoY. All 18 analysts rate it Buy, with a $78.94 price target. Key focus areas include LDD signings, margin trends, and 2027 guidance. Shares have risen 67% YTD.
BrightSpring Health Services (BTSG) generates 80% of revenue from specialty and institutional pharmacy services, with a strong structural moat due to low patient churn and recurring revenue. The company's 2026 outlook suggests it may be 10% undervalued, according to the analysis.
BrightSpring Health Services (BTSG) shares rose 4.8% after BMO Capital analyst Sean Dodge reaffirmed an Outperform rating and $70 price target. The stock is volatile, with 16 moves over 5% in the past year. Q2 revenue grew 23% YoY to $3.87B, with non-GAAP EPS of $0.45, beating expectations. The company is up 56.3% YTD but trades 17.7% below its 52-week high.
